Table 3 US FDA approved therapeutic agents for the clinical use in the treatment of PC
From: Recent advances and future perspectives in the therapeutics of prostate cancer
S. No | Therapeutic agents used | Type of therapeutic | Date of US FDA approval | Date of EMA approval | Date of NMPA approval |
|---|---|---|---|---|---|
1 | 68Ga-PSMA-11 | Diagnostic radiopharmaceutical agent | Mar 2022 | Â | Â |
2 | 177Lu-PSMA-617 | Therapeutic radiopharmaceutical agent | Mar 2022 | Â | Â |
3 | Abiraterone | Endocrine therapeutic agent | Apr 2011 | Sept 2011 | Dec 2019 |
4 | Cabazitaxel | Antineoplastic agents | Jun 2010 | Mar 2011 | Â |
5 | Dostarlimab-gxly | Immunotherapeutic agent | Aug 2021 | Â | Â |
6 | Degarelix | Endocrine therapeutic agents | Dec 2008 | Feb 2009 | July 2019 |
7 | Denosumab | Bone-targeting therapeutic agent | Nov 2010 | July 2011 | May 2019 |
8 | Darolutamide | Endocrine therapeutic agent | Jul 2019 | Mar 2020 | Feb 2021 |
9 | Enzalutamide | Endocrine therapeutic agent | Aug 2012 | Jun 2013 | Nov 2019 |
10 | Fluciclovine (18F) | Diagnostic radiopharmaceutical agent | May 2016 | May 2017 | Â |
11 | Olaparib | PARPi | May 2020 | Nov 2020 | Jun 2021 |
12 | Padeliporfin | Antineoplastic agents | Â | Sept 2017 | Â |
13 | Pembrolizumab | Immunotherapeutic agent | May 2017 | Â | Â |
14 | Piflufolastat F 18 | Diagnostic radiopharmaceutical agent | May 2021 | Â | Â |
15 | Radium-223 dichloride | Therapeutic radiopharmaceutical agent | May 2013 | Nov 2013 | Aug 2020 |
16 | Relugolix | Endocrine therapeutic agent | Dec 2020 | Mar 2022 | Â |
17 | Rucaparib | Antineoplastic agents | May 2020 | Â | Â |
18 | Sipuleucel-T | Immunotherapeutic agent | Apr 2010 | Sept 2013 | Â |
19 | Zoledronic acid | Bone-targeting therapeutic agent | Feb 2002 | Mar 2001 | Dec 2018 |